Evidence map›Paper›PMID 28620458›Full record

ReviewF1000Research2017

Reproducibility2020: Progress and priorities.

Leonard P Freedman, Gautham Venugopalan, Rosann Wisman

Abstract readReview
In one paragraph

Review in F1000Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. The Open Field Test as a Tool for Behaviour Analysis in Pigs: Recommendations for Set-Up Standardization - A Systematic Review.European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes · 2023
    Pooled it
  2. Trial
  3. Article
  4. A quality framework for cryopreserved rodent disease models: INFRAFRONTIER quality principles in EMMA archiving and distribution.Mammalian genome : official journal of the International Mammalian Genome Society · 2025
    Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Multicompartmental analysis of the murine pulmonary immune response by spectral flow cytometry.American journal of physiology. Lung cellular and molecular physiology · 2023
    Article
  13. Optimizing anesthesia and delivery approaches for dosing into lungs of mice.American journal of physiology. Lung cellular and molecular physiology · 2023
    Article
  14. Article
  15. Article
  16. INFRAFRONTIER quality principles in systemic phenotyping.Mammalian genome : official journal of the International Mammalian Genome Society · 2022
    Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Leonard P FreedmanGlobal Biological Standards Institute, Washington, DC, 20036, USA.ORCID 0000-0003-2352-4037
Gautham VenugopalanGryphon Scientific, LLC, Takoma Park, MD, 20912, USA.
Rosann WismanGlobal Biological Standards Institute, Washington, DC, 20036, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The preclinical research process is a cycle of idea generation, experimentation, and reporting of results. The biomedical research community relies on the reproducibility of published discoveries to create new lines of research and to translate research findings into therapeutic applications. Since 2012, when scientists from Amgen reported that they were able to reproduce only 6 of 53 "landmark" preclinical studies, the biomedical research community began discussing the scale of the reproducibility problem and developing initiatives to address critical challenges. Global Biological Standards Institute (GBSI) released the "Case for Standards" in 2013, one of the first comprehensive reports to address the rising concern of irreproducible biomedical research. Further attention was drawn to issues that limit scientific self-correction, including reporting and publication bias, underpowered studies, lack of open access to methods and data, and lack of clearly defined standards and guidelines in areas such as reagent validation. To evaluate the progress made towards reproducibility since 2013, GBSI identified and examined initiatives designed to advance quality and reproducibility. Through this process, we identified key roles for funders, journals, researchers and other stakeholders and recommended actions for future progress. This paper describes our findings and conclusions.

Indexed as

preclinical researchprotocol sharingreagents and reference materialsreproducibilityscientific publicationsstudy design

Identifiers

PMID28620458
PMCPMC5461896

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.